Ondine Biomedical reports successful topline data from phase II nasal photodisinfection trial

Ondine Biomedical Inc (AIM:OBI) president and chief technology officer Dr Nicolas Loebel tells Proactive’s Stephen Gunnion that the results from the firm’s phase II BENEFIT-APDT clinical trial provide further clinical support for its process of using nasal photodisinfection to reduce post-operative complications caused by infection.

Loebel telling Proactive that surgical site infections are an important area to focus on as “they are really infections that shouldn’t exist”.

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews